CD19-CD22 CAR-T cells is under clinical development by Shanghai Biomed-Union Biotechnology and currently in Phase II for Unspecified B-Cell Lymphomas. According to GlobalData, Phase II drugs for Unspecified B-Cell Lymphomas does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the CD19-CD22 CAR-T cells LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
CD19-CD22 CAR-T cells overview
The therapeutic candidate is under development for unspecified B cell lymphomas. It is administered through intravenous route. The therapy constitutes of genetically manipulated autologous T cells which express chimeric antigen receptor (CAR) targeting cells expressing B lymphocyte antigen CD19 (CD19) and cells expressing B cell receptor CD22 (CD22).
It was also under development for third line therapy for the treatment of relapsed or refractory B cell lymphoma and relapsed or refractory acute B lymphocytic leukemia.
For a complete picture of CD19-CD22 CAR-T cells’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
